Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

Recent & Breaking News (TSX:ONC)

The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares

Benzinga.com  October 10, 2018

Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies

GlobeNewswire October 2, 2018

Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC

GlobeNewswire September 28, 2018

Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference

GlobeNewswire September 26, 2018

Oncolytics Biotech® Provides Corporate and Clinical Update

GlobeNewswire September 19, 2018

Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care

GlobeNewswire September 17, 2018

Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

GlobeNewswire September 10, 2018

Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program

GlobeNewswire September 6, 2018

Oncolytics Biotech® Reports 2018 Second Quarter Results

GlobeNewswire August 3, 2018

Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference

GlobeNewswire July 31, 2018

Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares

GlobeNewswire June 5, 2018

Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting

GlobeNewswire June 4, 2018

Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares

GlobeNewswire June 1, 2018

Oncolytics Biotech® Announces Listing on Nasdaq Capital Market

GlobeNewswire June 1, 2018

Oncolytics Biotech® Announces Public Offering of Common Shares

GlobeNewswire May 31, 2018

Oncolytics Biotech® Announces New OTCQX Ticker Symbol

GlobeNewswire May 29, 2018

Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone

GlobeNewswire May 25, 2018

Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Benzinga.com  May 23, 2018

Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Phase 2 Second Line Pancreatic Cancer Study

GlobeNewswire May 17, 2018

Oncolytics Biotech® Announces Publication of REOLYSIN® Abstract for the ASCO 2018 Annual Meeting

GlobeNewswire May 16, 2018